XML 78 R21.htm IDEA: XBRL DOCUMENT v2.4.1.9
14. SEGMENTS
 9 Months Ended 12 Months Ended
Dec. 31, 2014
Mar. 31, 2014
Segment Reporting [Abstract]    
SEGMENTS

We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and Exosome Sciences, Inc., which represents our diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being developed.

 

Aethlon’s revenue is generated primarily from government contracts to date and Exosome Sciences, Inc. does not yet have any revenues. We have not included any allocation of corporate overhead to the Exosome Sciences, Inc. segment.

 

The following tables set forth certain information regarding our segments and other operations that conforms to the consolidated balance sheet and statement of operations presented in this Report:

 

   

Nine Months Ended

December 31,

  
    2014     2013  
Revenues:                
Aethlon   $ 563,805     $ 916,796  
Exosome Sciences, Inc.     –       –  
Total Revenues   $ 563,805     $ 916,796  
                 
Operating Losses:                
Aethlon   $ (2,156,769 )   $ (2,065,212 )
 Exosome Sciences, Inc.     (703,411 )     (180,722 ) 
Total Operating Loss   $ (2,860,180 )   $ (2,245,934 )
                 
Net Losses:                
Aethlon   $ (5,347,716 )   $ (5,735,474 )
Exosome Sciences, Inc.     (703,411 )     (185,305 ) 
Net Loss Before Non-Controlling Interests   $ (6,051,127 )   $ (5,920,779 )
                 
Cash:                
Aethlon   $ 2,446,820     $ 588,066  
Exosome Sciences, Inc.     328,915       1,266,875  
Total Cash   $ 2,775,735     $ 1,854,941  
                 
Total Assets:                
Aethlon   $ 2,735,913     $ 777,004  
Exosome Sciences, Inc.     420,582       1,328,004  
Total Assets   $ 3,156,495     $ 2,105,008  
                 
Capital Expenditures:                
Aethlon   $ –     $ 2,750  
Exosome Sciences, Inc.     –       58,743  
Capital Expenditures   $ –     $ 61,493  
                 
Depreciation and Amortization:                
Aethlon   $ 13,328     $ 7,195  
Exosome Sciences, Inc.     14,686       6,964  
Total Depreciation and Amortization   $ 28,014     $ 14,159  
                 
Interest Expense:                
Aethlon   $ 285,229     $ 325,364  
Exosome Sciences, Inc.     –       4,583  
Total Interest Expense   $ 285,229     $ 329,947  

 

14. SEGMENTS

 

We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being developed. ESI did not have any operations in the fiscal year ended March 31, 2013.

 

Aethlon’s revenue is generated primarily from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead to the ESI segment.

 

The following tables set forth certain information regarding our segments and other operations that conforms to the consolidated balance sheet and statement of operations presented in this Report:

 

    Fiscal Years Ended March 31,  
    2014     2013  
Revenues:                
  Aethlon   $ 1,623,769     $ 1,230,004  
  ESI     –       –  
    Total Revenues   $ 1,623,769     $ 1,230,004  
                 
Operating Losses:                
  Aethlon   $ (2,651,863 )   $ (3,575,354 )
  ESI     (404,065 )     –  
    Total Operating Loss   $ (3,055,928 )   $ (3,575,354 )
                 
Net Losses:                
  Aethlon   $ (13,357,232 )   $ (4,892,040 )
  ESI     (81,730 )     –  
    Net Loss Before Non-Controlling Interests   $ (13,438,962 )   $ (4,892,040 )
                 
Cash:                
  Aethlon   $ 208,259     $ 125,274  
  ESI     1,042,020       –  
    Total Cash   $ 1,250,279     $ 125,274  
                 
Total Assets:                
  Aethlon   $ 597,026     $ 496,694  
  ESI     1,098,076       –  
    Total Assets   $ 1,695,102     $ 496,694  
                 
Capital Expenditures:                
  Aethlon   $ 37,313     $ –  
  ESI     58,743       –  
    Capital Expenditures   $ 96,056     $ –  
                 
Depreciation and Amortization:                
  Aethlon   $ 11,549     $ 10,484  
  ESI     9,538       –  
    Total Depreciation and Amortization   $ 21,087     $ 10,484  
                 
Interest Expense:                
  Aethlon   $ 1,282,638     $ 1,132,314  
  ESI     4,583       –  
    Total Interest Expense   $ 1,287,221     $ 1,132,314